XTalks

MARCH 8, 2022

On International Women’s Day, Xtalks is celebrating women’s leadership in the life sciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation. Challenges in Women’s Leadership.

Life Science 105

Life Science Gene Therapy DNA Vaccination 105

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. As tech experts call for improved regulation and a halt to the development of AI, we take a look at how one company, Atomic AI, is using it to develop RNA-targeting treatments for a range of diseases.

RNA 52

RNA Medicine Engineer Drugs 52

pharmaphorum

JANUARY 19, 2022

The collaboration aims to “close the gap between single-cell RNA sequencing wet-lab services and single-cell data analysis solutions,” which will allow scientists to study the finest details that can be hard to access. Research Instruments is the main distributor for genomic and life science research products in the region.

RNA 72

RNA Research Life Science Bioinformatics 72

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

Drug Discovery World

MARCH 6, 2023

The post Institiute gives a boost to five new life science start-ups appeared first on Drug Discovery World (DDW). In becoming a part of the Venture Lab programme, the early-stage companies also get an exclusive opportunity to apply for €1.4 million in follow-up funding through BII’s Venture House program.

Life Science 52

Life Science RNA Drugs Business Development 52

Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 52

RNA Engineer Life Science Drugs 52

XTalks

SEPTEMBER 15, 2021

With RNA being the popular new “it” molecule in genetic research, Ayesha discusses Eli Lilly’s new partnership with biotech company ProQR to develop RNA-based therapeutics in this episode. billion deal will see Lilly leverage ProQR’s proprietary RNA editing platform to develop targets of interest.

RNA 52

RNA Life Science Development Genetics 52

XTalks

MARCH 21, 2022

Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.

RNA 98

RNA Vaccination Vaccine Sales 98

BioTech 365

JUNE 2, 2021

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency First proof-of-concept in vivo data for RNA editing using endogenous … Continue reading →

Life Science 40

Life Science In-Vivo RNA 40

XTalks

MARCH 23, 2022

Moderna hit back at Alnylam, accusing it of “blatant opportunism” and saying that it has worked for years on a different version of the RNA delivery technology. Read the full articles here: Alnylam Files Lawsuits Against Pfizer and Moderna Over Patent Infringement of RNA Delivery Technology.

Life Science 52

Life Science RNA Vaccination Vaccine 52

XTalks

MAY 10, 2023

Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Read the full articles here: Arexvy Becomes World’s First RSV Vaccine Qalsody (Tofersen) Becomes First-of-Its-Kind Treatment for ALS The weekly podcast is available for streaming every Wednesday on Spotify , Apple Music and wherever you stream your podcasts.

Life Science 52

Life Science Vaccination Vaccine FDA Approval 52

BioSpace

SEPTEMBER 8, 2021

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

RNA 90

RNA Licensing Licensing Life Science 90

BioSpace

AUGUST 9, 2021

Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.

Life Science 102

Life Science RNA 102

STAT News

JANUARY 19, 2023

Does science need billionaires? And do normal people care about messenger RNA? Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica, involving a Scientologist CEO and secretive investor seeking redemption after the worst trade of his life.

Vaccination 115

Vaccination Vaccine Life Science RNA 115

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.

Life Science 111

Life Science Vaccination Vaccine Gene 111

pharmaphorum

JULY 19, 2021

Drugs harnessing the potential of modified RNA, antisense and siRNA oligonucleotides, antibody–drug conjugates and nanomedicines will become as important as today’s ‘small molecule’ drugs, reaching potential market values into the hundreds of billions – if the potential can be realised through innovation support and industry collaboration.

Life Science 52

Life Science Medicine RNA Vaccination 52

Pharmaceutical Technology

JANUARY 12, 2023

The collaboration will use the vector biology, manufacturing capabilities and the drug development experience of Solid Biosciences and Phlox Therapeutics’ knowledge in genetic cardiomyopathies and RNA therapies. Solid Biosciences stated that the partnership boosts its scientific capabilities along with commercial potential in cardiac therapy.

RNA 130

RNA Gene Therapy Genetics Genetic Disease 130

Drug Discovery World

DECEMBER 23, 2022

According to a report by Cpl Life Sciences and Vacancysoft, 2022 has remained consistently steady for the life sciences industry in Europe in terms of recruitment, though still below 2021 levels. . The UK leads the way in terms of hiring activity by country, with 1,538 jobs year-to-date for CROs. compared to 2021. .

Life Science 52

Life Science RNA Clinical Trials Clinical Trials 52

Pharmaceutical Technology

APRIL 3, 2023

The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Sartorius , through its French listed sub-group Sartorius Stedim Biotech , has signed an agreement to acquire Polyplus for €2.4bn ($2.6bn).

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

Drug Discovery World

JANUARY 9, 2024

Italy-based Resalis Therapeutics has closed a €10 million ($11 million) Series A financing round led by Sunstone Life Science Ventures with participation from existing investors. In conjunction with the financing, Claus Andersson, General Partner of Sunstone Life Science Ventures, will join Resalis’ Board of Directors.

Drugs 52

Drugs Life Science RNA Clinical Trials 52

Drug Discovery World

JANUARY 24, 2023

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reportedly has ‘high ambitions’ for rapid global growth. Key to these ambitions will be a new vaccine research, development and manufacturing facility in the UK, creating new jobs and building up the UK’s life sciences ecosystem.

Life Science 52

Life Science Vaccination Vaccine RNA 52

XTalks

OCTOBER 7, 2020

LabCorp – a leading global life sciences company based in Burlington, North Carolina that focuses on advancing health and guiding patient care decisions – announced that it is the first commercial laboratory to receive an EUA from the FDA for the new, innovative, high-speed test.

Reagent 98

Reagent RNA Life Science FDA Approval 98

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Pharma is also keen to access next generation RNA platforms, such as self-amplifying RNAs derived from the genomes of positive-strand RNA viruses.

RNA 52

RNA Pharma Companies Antibody Life Science 52

XTalks

JANUARY 3, 2024

Through the licensing deal, Novartis will gain access to Voyager’s CAPSID discovery platform, an RNA-based screening platform designed to facilitate the rapid discovery of experimental gene therapies. Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER capsids and other intellectual property.

Gene Therapy 52

Gene Therapy Gene Licensing Licensing 52

XTalks

FEBRUARY 3, 2022

Related: Eli Lilly Pursues RNA Editing in New Partnership with ProQR. In the news release from IDA outlining Lilly’s new Irish manufacturing plant, the agency said Ireland has made a name for itself as a life sciences and biopharma manufacturing hub. This includes the company’s foray into RNA technologies such as RNA editing.

Manufacturing 52

Manufacturing RNA Life Science Antibody 52

XTalks

JUNE 20, 2022

Small interfering RNAs (siRNAs) are a promising class of therapeutic modalities that involve a double-stranded RNA molecule (20 to 25 bp long) which can target and cease the translation of a disease-related mRNA. 1 (transforming growth factor beta1) and the enzyme COX-2 (cyclooxygenase-2) is strongly linked with SCC development.

RNA 96

RNA Clinical Trials Clinical Trials Dermatology 96

Drug Discovery World

APRIL 27, 2023

The first quarter of 2023 has seen deal flow continue for UK life science and biotech companies at all stages of development, new data from the UK BioIndustry Association and Clarivate shows. million across 20 deals, with an average deal size of £13 ($16.1) Prokarium secured £24.9 ($30.8) million raised by existing public companies.

Life Science 52

Life Science Gene Therapy Bacteria RNA 52

XTalks

OCTOBER 21, 2020

In addition, Berrio and colleagues discovered other novel targets of positive selection, namely within genes encoding Nsp4 and Nsp16, which are viral enterotoxins important for the stability of the RNA structure of the virus. Moreover, Berrio says the changes likely affected the folding and function of viral RNA.

RNA 98

RNA Protein Genome Genomics 98

Drug Discovery World

MARCH 13, 2024

With government support and strong academic institutions, does Singapore have what it takes to become a global centre for life sciences? DDW’s Diana Spencer explores how the country is turning pioneering science into a successful biotech industry. The post Can Singapore become a global hub for biotech?

Life Science 69

Life Science Genome Genomics Research 69

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). .

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 75

Drugs Life Science Gene Therapy Genome 75

XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

APRIL 14, 2022

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. CHAIRS FOR 2022: •Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon. EARLY-BIRD RATES: ?BOOK

RNA 52

RNA Clinical Trials Clinical Trials Life Science 52

pharmaphorum

AUGUST 11, 2020

MDC already has established working relationships with many life science organisations across the region and provides input into the LEP’s regional life sciences strategy. The funding will be used to create a regional consortium and develop the full stage bid.

Medicine 52

Medicine Life Science Development RNA 52

pharmaphorum

DECEMBER 24, 2020

AZ’s vaccine, dubbed AZD1222, is stored at normal refrigerator temperatures while the Pfizer/BioNTech and Moderna shots need to be kept at around -70C and -20C respectively to maintain the integrity of their RNA structure. I would expect some news pretty shortly, I doubt we will make Christmas now but just after Christmas I would expect.

Vaccination 126

Vaccination Vaccine Regulation Life Science 126

Drug Discovery World

JULY 11, 2023

Tim Lowery , President, JSR Life Sciences, asks whether artificial intelligence can do for life sciences what it has done in other sectors and whether these tools can keep up with the complexities of human biology. So, where do we go from here to realise their potential in life sciences?

Big Data 40

Big Data Development Life Science Drugs 40

XTalks

AUGUST 5, 2020

In recent webinars by Genuity Science, formerly known as WuXi NextCODE, experts from the biotech and pharma industries spoke about leveraging the power of single cell RNA sequencing platforms and solutions in conjunction with machine learning technologies such as AI in cell biology and disease research.

Gene Expression 112

Gene Expression Development RNA Drugs 112